Background
Methods
Patients
Treatment plan
Evaluation of treatment and statistical analysis
Results
Patient characteristics
All (N = 83) (%) | No ascites (N = 43) (%) | Small to moderate ascites (N = 26) (%) | Massive ascites (N = 14) (%) | ||
---|---|---|---|---|---|
Age | Median (range) | 67 (23–83) | 68 (48–78) | 64.5 (23–83) | 67.5 (32–81) |
Gender | Male* | 60 (72) | 37 (86) | 15 (58) | 8 (57) |
ECOG PS | 0* | 48 (58) | 28 (65) | 18 (69) | 2 (14) |
1 | 25 (30) | 13 (30) | 5 (19) | 7 (50) | |
2* | 10 (12) | 2 (5) | 3 (12) | 5 (36) | |
Histological Type | Diffuse | 47 (57) | 20 (46) | 17 (65) | 10 (71) |
Intestinal | 36 (43) | 23 (54) | 9 (35) | 4 (29) | |
Number of previous CTX | 1 | 59 (71) | 29 (67) | 18 (69) | 12 (86) |
≥2 | 24 (29) | 14 (33) | 8 (31) | 2 (14) | |
Gastrectomy | Yes | 31 (37) | 18 (42) | 7 (27) | 6 (43) |
Target lesion | Yes | 45 (54) | 28 (65) | 12 (46) | 5 (36) |
Site of metastasis | Lymph node | 56 (67) | 34 (79) | 15 (58) | 7 (50) |
Liver | 22 (27) | 13 (30) | 7 (27) | 2 (14) | |
Peritoneal | 49 (59) | 11 (26) | 24 (92) | 14 (100) | |
Ovary* | 10 (12) | 1 (2) | 5 (19) | 4 (29) | |
Number of metastases | 1–2* | 70 (84) | 39 (91) | 19 (73) | 12 (86) |
≥ 3 | 13 (16) | 4 (9) | 7 (27) | 2 (14) |
Treatment results and toxicity
All (N = 83) (%) | No ascites (N = 43) (%) | Small to moderate ascites (N = 26) (%) | Massive ascites (N = 14) (%) | P valuea | |||||
---|---|---|---|---|---|---|---|---|---|
All (%) | Gr3-4 (%) | All (%) | Gr3-4 (%) | All (%) | Gr3-4 (%) | All (%) | Gr3-4 (%) | ||
Hematological toxicity | |||||||||
Any | 70 (84) | 52 (63) | 35 (81) | 22 (51) | 24 (92) | 20 (77) | 11 (79) | 10 (71) | 0.076 |
Neutropenia | 61 (73) | 40 (48) | 30 (70) | 19 (44) | 21 (81) | 19 (73) | 10 (71) | 8 (57) | 0.064 |
Leukopenia | 59 (71) | 32 (39) | 29 (67) | 11 (26) | 20 (77) | 14 (54) | 10 (71) | 7 (50) | 0.041 |
Anemia | 27 (33) | 8 (10) | 15 (35) | 4 (9) | 9 (35) | 3 (12) | 3 (21) | 1 (7) | 0.49 |
Thrombocytopenia | 8 (10) | 3 (4) | 4 (9) | 3 (7) | 3 (12) | 0 | 1 (7) | 0 | 0.72 |
Nonhematological toxicity | |||||||||
Any | 76 (92) | 10 (12) | 39 (91) | 4 (9) | 24 (92) | 4 (15) | 13 (93) | 2 (14) | 0.72 |
Fatigue | 38 (46) | 0 | 20 (47) | 0 | 9 (35) | 0 | 9 (64) | 0 | 0.23b |
Neuropathy | 38 (46) | 0 | 23 (53) | 0 | 11 (42) | 0 | 6 (43) | 0 | 0.87b |
Anorexia | 37 (45) | 6 (7) | 17 (40) | 2 (5) | 12 (46) | 3 (12) | 8 (57) | 1 (7) | 0.56 |
Hypertention | 24 (29) | 2 (2) | 11 (26) | 0 | 10 (38) | 1 (4) | 3 (21) | 1 (7) | 0.27 |
Peripheral edema | 23 (28) | 0 | 11 (26) | 0 | 7 (27) | 0 | 5 (36) | 0 | 0.74b |
Proteinuria | 9 (11) | 0 | 4 (9) | 0 | 5 (19) | 0 | 0 | 0 | 0.12b |
Diarrhea | 8 (10) | 0 | 6 (14) | 0 | 1 (4) | 0 | 1 (7) | 0 | 0.36b |
Epistaxis | 8 (10) | 0 | 5 (12) | 0 | 1 (4) | 0 | 2 (14) | 0 | 0.62b |
Febrile netropenia | 3 (4) | 3 (4) | 3 (7) | 3 (7) | 0 | 0 | 0 | 0 | 0.26 |
All (N = 83) (%) | No ascites (N = 43) (%) | Small to moderate ascites (N = 26) (%) | Massive ascites (N = 14) (%) | P value* | |||||
---|---|---|---|---|---|---|---|---|---|
All (%) | ≥ Gr3(%) | All (%) | ≥ Gr3(%) | All (%) | ≥ Gr3(%) | All (%) | ≥ Gr3(%) | ||
Hypertension | 24 (29) | 2 (2) | 11 (26) | 0 | 10 (38) | 1 (4) | 3 (21) | 1 (7) | 0.27 |
Bleeding or haemorrhage | 19 (23) | 2 (2) | 9 (21) | 2 (5) | 6 (23) | 0 | 4 (29) | 0 | 0.39 |
Proteinuria | 9 (11) | 0 | 4 (9) | 0 | 5 (19) | 0 | 0 | 0 | 0.16** |
Liver injury or failure | 6 (7) | 0 | 2 (5) | 0 | 2 (8) | 0 | 2 (14) | 0 | 0.48** |
Gastrointestinal haemorrhage | 5 (6) | 2 (2) | 3 (7) | 2 (5)a | 1 (4) | 0 | 1 (7) | 0 | 0.39 |
Gastrointestinal perforation | 1 (1) | 1 (1) | 0 | 0 | 1 (4) | 1 (4) | 0 | 0 | 0.33 |
Infusion-related reaction | 0 | 0 | 0 | 0 | 1 (4) | 0 | 0 | 0 | 0.33** |
Efficacy
Groups | N | CR | PR | SD | PD | ORR (%) | DCR (%) | P value* |
---|---|---|---|---|---|---|---|---|
All patients | 45 | 0 | 14 | 22 | 9 | 31.8 | 77.3 | 0.54 |
No ascites | 28 | 0 | 11 | 14 | 3 | 39.2 | 89.2 | |
Small to moderate ascites | 12 | 0 | 2 | 6 | 4 | 16.7 | 66.7 | |
Massive ascites | 5 | 0 | 1 | 2 | 2 | 20.0 | 60.0 |
Groups | N | Disappeared (N) (%) | Decreased (N) (%) | No change (N) (%) | Increased (N) (%) | NE (N) (%) | P value* |
---|---|---|---|---|---|---|---|
All patients with ascites | 40 | 3 (7.5) | 11 (27.5) | 12 (30) | 12 (30) | 2 (5) | 0.88 |
Small to moderate ascites | 26 | 3 (12) | 6 (23) | 9 (35) | 8 (31) | 0 | |
Massive ascites | 14 | 0 | 5 (36) | 3 (21) | 4 (29) | 2 (14) |